Sanofi and AB-Biotics create formula to ease colic in babies
<p>The probiotic formula, developed by the Catalan biotechnology company, will be the first that pharmaceutical corporation Sanofi will market in Spain</p>
Baby colic affects between 8% and 40% of all infants in the first three months of life. Although the specific cause is unknown, the condition is characterized by inconsolable crying and irritability. The patented AB-Kolicare® formula helps reduce crying in 67.5% of infants with the condition, on average, after 14 days of treatment, according to a clinical study conducted by Catalan biotechnology firm AB-Biotics.
The AB-Kolicare® formula combines two different probiotic strains: Bifidobacterium longum(CECT 7894) and Pediococcus pentosaceus (CECT 8330). This is the first probiotic that multinational pharmaceutical corporation Sanofi, with Spanish headquarters in Barcelona, will launch on the national market. The formula will be distributed under the brand name Sanogermina with two different products: Sanogermina AB-Kolicare® and Sanogermina Flora Niños.
“The agreement with Sanofi is an excellent example of the synergies that can arise from collaborations between a large multinational corporation like Sanofi and a small biotech firm like AB-Biotics. For us, its validation of the quality of our human team and an opportunity to continue developing our gastro-pediatric line of innovative probiotics internationally with a benchmark partner,” say AB-Biotics co-founders Miquel Àngel Bonachera and Sergi Audivert.
For Josep Infesta, vice-president of Sanofi Consumer Healthcare for Europe, “Sanofi is moving into the probiotics market in Spain by launching two products that contain the AB-Kolicare® formula, with the firm intention of expanding our portfolio over the coming years.”
